University of California

California Institute of Technology

1200 Pharma LLC

Neil A O'Brien

Dennis J Slamon

Martina S McDermott

Michael J Palazzolo

Dylan Conklin

Brian M Stoltz

Michael D Bartberger

Brendan M O'Boyle

Scott C Virgil

Corey M Reeves

Alexander W Sun

Justin A Hilf

Oliver C Loson

Peter Bowers

Erika Von Euw

Steven J Wittenberger

Martina Mcdermott

Mike Palazzolo

The present disclosure provides compounds and compositions that are CDK inhibitors selective for CDK4 and/or CDK6, and methods of use thereof.

CDK inhibitors and uses thereof

The present disclosure provides compounds and compositions that are inhibitors of ERK1, ERK2, or both, and methods of use thereof.

ERK inhibitors and uses thereof

Described herein are methods for inhibiting a solid tumor expressing claudin-6 in a human subject, comprising administering to the human subject an effective amount of a composition comprising conjugates of a CLDN6-specific antigen-binding protein covalently bound to heterologous moieties comprising structural formula (I):

Dosage of claudin-6 conjugates for cancer treatment

The present disclosure provides antigen-binding proteins which bind to Claudin-18.2 (CLDN18.2); bispecific antigen-binding proteins which bind to CLDN18.2 and a second antigen; and conjugates thereof. In various aspects, the antigen-binding proteins bind to Extracellular Loop 1 (EL1) of the extracellular domain of CLDN18.2. Related polypeptides, nucleic acids, vectors, host cells, and conjugates are further provided herein. Kits and pharmaceutical compositions comprising such entities are moreover provided. Also provided are methods of making an antigen-binding protein and methods of treating a subject having cancer.

CLAUDIN18 antibodies and methods of treating cancer

The present disclosure provides antigen-binding proteins which bind to Claudin-6 (CLDN6). In various aspects, the antigen-binding proteins bind to Extracellular Loop 2 (EL2) of the extracellular domain of CLDN6. Related polypeptides, nucleic acids, vectors, host cells, and conjugates are further provided herein. Kits and pharmaceutical compositions comprising such entities are moreover provided. Also provided are methods of making an antigen-binding protein and methods of treating a subject having cancer.

Claudin-6 antibodies and drug conjugates

Claudin18 antibodies and methods of treating cancer

Growing community of inventors

Los Angeles, CA, United States of America

Neil A O'Brien